NCT04417088View on ClinicalTrials.gov

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2024

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Carboplatin

Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain

DEVICE

Exablate BBBD

BBB opening via Exablate Neuro Type 2 system with microbubble resonators.

Trial Locations (4)

21201

University of Maryland, Baltimore

44195

Cleveland Clinic, Cleveland

94304

Stanford University, Palo Alto

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT04417088 - Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | Biotech Hunter | Biotech Hunter